Skip to main content

Genetics in Type 2 Diabetes May Influence Beta Cell Mass


May 29, 2012 (Florence, Italy) — In patients with newly diagnosed type 2 diabetes, genetic differences might influence beta cell functional mass, new research suggests.
Sara Bonetti, MD, from the University of Verona and the Azienda Ospedaliera Universitaria Integrata, in Italy, and colleagues presented the findings here at the Joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology.
"This cohort of newly diagnosed type 2 diabetic patients was useful for our purposes because of the absence of the potentially confounding effects of long-lasting antidiabetic treatments and because of the limited impact of duration and severity of hyperglycemia on metabolic phenotypes," Dr. Bonetti told Medscape Medical News.
According to Dr. Bonetti and colleagues, common genetic variability is already known to influence beta cell functional mass in type 2 diabetes, but the way in which this occurs is not clear.
To investigate the role of genetics in beta cell mass, the researchers studied 590 drug-naïve, glutamic-acid-decarboxylase-negative patients newly diagnosed with type 2 diabetes. Median age was 60 years and average body mass index was 29.3 kg/m².
Dr. Bonetti and colleagues assessed beta cell functional mass using mathematical modeling of glucose/C-peptide curves during multiple oral glucose tolerance tests. Insulin sensitivity was measured using the insulin clamp technique.
Forty-five single-nucleotide polymorphisms (SNPs) were selected to represent over 90% of the common genetic variability observed in diabetes. The SNPs came from 8 genes involved in maturity onset diabetes of the young (MODY) and 2 genes associated with neonatal diabetes mellitus (NDM).
The researchers measured both derivative and proportional control of beta cell function. Derivative control measures the capability of beta cells to respond to the rate of increase in glucose concentration (i.e., it takes into account the actual and the baseline glucose concentration). Proportional control measures the capability of beta cells to respond to glucose concentration at a given moment in time.
They found that allelic variants of 4 SNPs — rs1303722 and rs882019 of glucokinase, rs7310409 of HNF1A, and rs5219 of KCNJ11 (a known type 2 diabetes risk variant) — were significantly associated with changes in derivative control of beta cell function (P = .007 to .030).
Allelic variants of 5 other SNPs — rs2869084 and rs6031544 of HNF4A, rs10774580 of HNF1A, rs1801262 of NEUROD1, and rs7129639 of ABCC8 — were found to influence proportional control of beta cell function (P = .001 to .040).
Of the 45 SNPs, 1 was found to be associated with insulin sensitivity (P = .047).
"Common variability of MODY and NDM genes is significantly associated to beta cell functional mass in patients with type 2 diabetes, potentially playing a role in the pathophysiology of the disease and in its metabolic prognosis," Dr. Bonetti and colleagues conclude.
According to Dr. Bonetti, it is possible that genetics will be used in the future to infer metabolic phenotypes that cannot be measured with standard clinical tools, and to personalize diagnosis and treatment.
However, she pointed out that many questions remain unanswered, because "type 2 diabetes is a complex disease and all genetic factors identified so far explain only a small part of the disease."
Vincenzo Trischitta, MD, associate professor of endocrinology at University La Sapienza in Rome, Italy, noted that it is well known that the genes studied modulate insulin secretion, so the findings are not surprising.
"Some data have been previously reported on the role of common variants of monogenic diabetes genes on abnormal glucose homeostasis," Dr. Trischitta told Medscape Medical News. "It makes a lot of sense that some of these variants may, in fact, affect insulin secretion, the most potent determinant of glucose homeostasis."
According to Dr. Trischitta, these data are very important becaause they help to address the pathophysiology of insulin secretion. However, he explained, clinicians "have to be aware that...genetic data on common variants have clinical relevance neither for predicting disease onset nor for treatment choices." Currently, clinicians "should be encouraged to use traditional clinical markers, which perform quite well and are not costly."
This study was supported in part by a European Foundation for the Study of Diabetes/Novartis grant. Dr. Bonetti and Dr. Trischitta have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more